Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028316) INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028316 International Application No.: PCT/US2018/045105
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
C07K 14/54 (2006.01) ,A61K 47/60 (2017.01) ,A61K 47/54 (2017.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
52
Cytokines; Lymphokines; Interferons
54
Interleukins (IL)
[IPC code unknown for A61K 47/60][IPC code unknown for A61K 47/54]
Applicants:
AMGEN INC. [US/US]; One Amgen Center Drive Thousand Oaks, CA 91320-1799, US
Inventors:
ALI, Khaled, M.K.Z.; US
AGRAWAL, Neeraj, Jagdish; US
KANNAN, Gunasekaran; US
FOLTZ, Ian; US
WANG, Zhulun; US
BATES, Daren; US
MOCK, Marissa; US
TAKENAKA, Shunseke; US
Agent:
HONG, Julie, J.; US
KISSLING, Heather, R.; US
Priority Data:
62/540,69203.08.2017US
62/616,73312.01.2018US
Title (EN) INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT
(FR) MUTÉINES D'INTERLEUKINE-21 ET MÉTHODES DE TRAITEMENT
Abstract:
(EN) Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
(FR) L'invention concerne des mutéines d'IL-21 et des protéines de fusion les comprenant destinées à être utilisées dans des méthodes de traitement d'une maladie. Des conjugués, des acides nucléiques, des vecteurs, des cellules hôtes, des compositions pharmaceutiques et des kits associés sont en outre décrits. L'invention concerne également des procédés de préparation desdites mutéines d'IL-21 et de protéines de fusion les comprenant, ainsi que des méthodes de traitement d'un sujet en ayant besoin. Des protéines de liaison à l'antigène PD-1 sont en outre décrites.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)